10 Years of Excellence

Founded in 2003 and based in Rockville, MD, TriStar has pioneered the use of very high-density tissue arrays for truly large-scale analysis of gene/protein expression in human normal and cancer tissues. Our customers can now obtain valuable data and IP around the expression or amplification of their targets in statistically powerful numbers of high quality tissues with annotated clinical data. Essentially, we give “Clinical Significance to Molecular Targets”.

An emerging unmet need in oncology drug development today is service providers that offer both access to well-annotated specimens and sophisticated molecular analytical capabilities. We have aimed to address this by offering a range of services, histology labs, analytical platforms and access top academic opinion leaders. We offer our customers distinct advantages.

What We’ve Done

TriStar’s repositories access over 2.5 million archived samples including High-density Prognosis Tissue Micro arrays. These can substantially accelerate the validation of clinical biomarkers by the simultaneous screening of thousands of well-defined tissue samples. Analytical techniques include Immunohistochemistry (IHC), Fluorescence in-situ hybridization (FISH) or RNA in-situ hybridization (ISH). The target expression/amplification observed is co-related with clinical data (prognosis, progression, drug treatment & response).

TriStar also offers in-vitro and in-vivo screening of antibodies & small molecule compounds on the largest commercially available library of human cancer stem cells (CSCs). We offer contract research services as well as participate in joint development projects. CSCs represent a powerful tool for basic and translational researchers aimed at studying the pathogenic events that drive cancer initiation and progression, while providing crucial information for the development of therapeutic compounds targeting specific survival pathways of the tumorigenic population.